CELG was recommended by Nate’s Notes at $65.41 in Investment Digest issue 707, dated November 16, 2011.
“Despite the fact that I expect Celgene Corp. (CELG) to make its usual strong showing at this year’s American Society of Clinical Oncology (ASCO) meeting over the weekend, I am afraid that what was described as an ‘ugly’ chart last month has gotten even uglier... with today’s dramatic drop to just over $65 suggesting that $60 is also likely to be tested before all is said and done.
“As is the case with a number of our other larger positions, I am taking a few chips off the table again this month; however, as pointed out above (and many times before), if you are new to the newsletter, you are strongly encouraged to make this one of your first (and ultimately largest) positions. CELG is now a strong buy under $60 and a buy under $64.”
Nate Pile, Nate’s Notes, June 1, 2012